Recombinant Human Factor VII Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-1965

Recombinant Human Factor VII Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-1965
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag His
Host Species Human
Accession P08709
Synonym Coagulation factor 7, Coagulation factor VII, SPCA
Background Coagulation factor VII, also known as Serum prothrombin conversion accelerator, Factor VII, F7 and FVII, is a member of the peptidase S1 family. Factor VII is one of the central proteins in the coagulation cascade. It is an enzyme of the serine protease class, and Factor VII (FVII) deficiency is the most frequent among rare congenital bleeding disorders. Factor VII contains two EGF-like domains, one Gla (gamma-carboxy-glutamate) domain and one peptidase S1 domain. The main role of factor VII is to initiate the process of coagulation in conjunction with tissue factor (TF). Tissue factor is found on the outside of blood vessels, normally not exposed to the blood stream. The action of the Factor VII is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent and is produced in the liver. Upon vessel injury, tissue factor is exposed to the blood and circulating Factor VII. Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), factor Xa, IXa, XIIa, and the FVIIa-TF complex itself. Recombinant activated factor VII (rFVIIa) is a haemostatic agent, which was originally developed for the treatment of haemophilia patients with inhibitors against factor FVIII or FIX. FVIIa binds specifically to endothelial protein C receptor (EPCR), a known cellular receptor for protein C and activated protein C, on the endothelium. rFVIIa is a novel hemostatic agent, originally developed for the treatment of hemorrhage in hemophiliacs with inhibitors, which has been successfully used recently in an increasing number of nonhemophilic bleeding conditions.
Description A DNA sequence encoding the human F7 isoform B (P08709-2) (Met 1-Pro 444) was expressed, fused with a His tag at the C-terminus.
Source HEK293
Predicted N Terminal Ala 39
AA Sequence Met 1-Pro 444
Molecular Weight The secreted mature form of recombinant human F7 consists of 417 a.a. and predictes a molecular mass of 46.5 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh F7 is approximately 50 kDa.
Purity >95% as determined by SDS-PAGE
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity Please contact us for detailed information
Formulation Lyophilized from sterile PBS, pH 7.4.
Stability The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage For Research Use Only
Storage Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium.
Subcellular Location Secreted.
Protein Families Peptidase S1 family
Database References
Associated Diseases Factor VII deficiency (FA7D)
Tissue Specificity Plasma.

Gene Functions References

  1. TF-FVIIa/trypsin-mediated PAR2 activation leads to enhanced MMP-2 expression in human breast cancer cells contributing to tumor progression. PMID: 29870887
  2. The current meta-analysis suggested that polymorphism of R353Q in factor VII was not associated with the MI risk. PMID: 30278561
  3. The obtained results suggest a possible protective role of Gln353 and -122C alleles in Recurrent Miscarriage. PMID: 27504943
  4. FVIIa-antithrombin levels in early and late preeclampsia PMID: 28887028
  5. model predicts that small vesicles promote activation of FX by the extrinsic tenase (VIIa/TF) significantly better than large vesicles PMID: 28935233
  6. Low levels of FVII:C and FVIIa reflected the degree of consumption of the coagulation factor among paediatric sepsis patients with disseminated intravascular coagulation. PMID: 28492702
  7. Report a good correlation between the type of F7 mutation and/or polymorphisms and FVII:C levels, without a direct link between FVII:C and bleeding tendency in factor VII deficiencies. PMID: 28447100
  8. Polymorphism rs6046 of the FVII gene is associated with the development of fetal growth retardation in Central Russia. PMID: 28544373
  9. A common pathogenic mechanism, possibly a defective folding of the mutant proteins, was triggered by the FVII mutations. The misfolded state led to impaired trafficking of these proteins causing Endoplasmic reticulum retention, which would explain the low to very low FVII plasma levels observed in patients carrying these mutations. PMID: 29246447
  10. FVIIa-antithrombin but not FVIIa is a ligand for LRP1, and LRP1 contributes to the clearance of FVIIa-antithrombin in vivo PMID: 27614059
  11. heterozygotes for FVII deficiency show rare bleeding manifestations which are also present in the unaffected family members with normal FVII levels. This indicates that Factor VII activity levels played no role in the occurrence of the bleeding symptoms. Furthermore, FVII levels of around 0.40 IU/dl are capable of assuring a normal hemostasis. PMID: 28176610
  12. plasma FVIIa-AT has a thrombophilic role in total and cardiovascular mortality risk in patients with clinically stable stable coronary artery PMID: 27061056
  13. Family-based association study revealed that the G allele of Protein Z rs2273971, and haplotypes GA, CG, and CGA of Protein Z and factor VII had a significant effect on cerebral hemorrhage susceptibility. PMID: 27350683
  14. Our study findings suggest a link between FVII and AR in prostate cancer pathogenesis. PMID: 27434295
  15. Suggest that the hemostatic effect of pharmacological doses of rFVIIa in antibody-induced hemophilia mice stems from a TF-independent mechanism PMID: 26727350
  16. Large deletions play a minor but essential role in the mutational spectrum of the F7 and F10 genes. Copy number analyses (e. g. MLPA) should be considered if sequencing cannot clarify the underlying reason of an observed coagulopathy. Of note, in cases of combined FVII/FX deficiency, a deletion of the two contiguous genes might be part of a larger chromosomal rearrangement. PMID: 26540129
  17. Holders of the R allele had significantly higher activity of coagulation factor F7 (97.66 +/- 15.48 against 83.37 +/- 15.16, p = 0.002) and factor F2 (107.45 +/- 6.03 against 103.75 +/- 6.81, p = 0.023) than holders of the Q allele PMID: 27215039
  18. The aim of the study was to evaluate the molecular basis behind low levels of FVII activity (FVII:C) levels in a cohort of Brazilian patients. PMID: 25828579
  19. Decreased plasma levels of FVIIa in patients with deep vein thrombosis may indicate ongoing consumption of FVIIa and suggest a contributory role for TF in venous thrombus formation. PMID: 25891834
  20. The story of FVII well summarizes the efforts of both theoretical and clinical approaches in the characterization of a coagulation disorder, that is, among the rare bleeding conditions, most frequently encountered in clinical practice. PMID: 25973586
  21. Identified are the FVII gene mutations in the Chinese Han population of four unrelated FVII-deficient patients, and the effect of these mutations on the function of FVII molecule level has also been elucidated. PMID: 25767893
  22. Letter: large volume of distribution of rFVIIa explains the persistence of some clotting potential when FVII:C is no longer detectable in plasma of patients with inherited FVII deficiency. PMID: 24763923
  23. Structural differences in the carboxyl-terminus between the inherited FVII and the therapeutic molecules contributed to the immune response. A naturally-occurring, poorly secreted and 5-residue truncated FVII (FVII-462X) escaped inhibition. PMID: 25104096
  24. Polymorphism R353Q (coagulation factor VII) does not represent a protective or risk factor for acute myocardial infarction in young Mexican individuals PMID: 25393858
  25. Two heterozygous mutations of F7, g.11349G>A and g.11482T>G, is associated with hereditary coagulation factor deficiency. PMID: 25863091
  26. factor VIIa improved heat intolerance by attenuating hypothalamic neuronal apoptosis and damage. PMID: 25033928
  27. Results show that the conformational allosteric activation signal extends to the EGF1 domain in the light chain of factor VIIa (FVIIa). PMID: 25344622
  28. F7-323Ins10 was associated with lower factor VII levels, but not with individual intraventricular hemorrhage risk in preterm infants. PMID: 25179312
  29. Decanucleotide insertion polymorphism of factor VII significantly influences the risk of thrombosis in patients with essential thrombocythemia. PMID: 24617727
  30. High Coagulation factor VII expression is associated with breast cancer. PMID: 25447311
  31. Persistently high levels of factor VII is associated with insulin resisitance. PMID: 24344794
  32. The variability in Factor VII throughout the menstrual cycle in premenopausal women is no greater than for postmenopausal women or men. PMID: 24382103
  33. The obtained results suggest a probable protective role of -323P10 allele against the risk of miscarriage in women with > or = 3 recurrent pregnancy losses. PMID: 25219139
  34. plasma level is associated with ischemic stroke subtypes PMID: 24048512
  35. Results suggest no association between R353Q polymorphism for factor VII and the presence or progression of coronary artery disease in the Iranian population. PMID: 24469878
  36. Identification of a homozygous mutation in exon 8 of coagulation FVII that is responsible for factor VII deficiency in a Chinese pedigree. PMID: 23672839
  37. Eight missense mutations were identified on the Factor 7 gene (p.Cys82Tyr, p.Cys322Ser, p.Leu357Phe, p.Thr410Ala, c-57C>T) PMID: 23731332
  38. Data indicate that nanobilayers containing phosphatidic acid (PA) bound substantially more of two proteins, factor VIIa and activated protein C, than did equivalent bilayers containing phosphatidylserine (PS). PMID: 23879866
  39. Data indicate that the interlaboratory precision was better for normal specimens than for factor VII (FVII) <20 U/dL with a mean coefficient of variation (CV) of 17.2% per specimen. PMID: 23590660
  40. Polymorphisms in the coagulation factor VII gene modulate the susceptibility to coronary artery disease in Tunisian Arabs. PMID: 22932775
  41. Rab GTPases regulate endothelial cell protein C receptor-mediated endocytosis and trafficking of factor VIIa. PMID: 23555015
  42. elevated FVII levels, and the -323P0/10 but not R353Q polymorphism, constitute risk factors for ACS. PMID: 23275237
  43. Data indicate that hfVII-LC and hIgG1-Fc can effectively inhibit tumor growth and metastases in SCID mice with tissue factor (TF) over-expressing colon cancer. PMID: 23494077
  44. Data suggest that plasma FVIIa-AT complex (coagulation factor VII-antithrombin III) is higher in portal vein thrombosis (PVT; without cirrhosis) than in healthy subjects; no difference in FVIIa-AT complex is observed in cirrhosis with/without PVT. PMID: 22958499
  45. Report comprehensive molecular analysis of FVII deficiency affected patients in North Tunisia. PMID: 22873696
  46. Prothromin genetic mutatation is one of the risk factor in the development of venous thromboembolism and myocardial infarction. PMID: 23382263
  47. glucose deprivation enhanced F7 expression in a mechanism reliant on prior ATF4 upregulation primarily due to increased transcription from the ATF4 gene. PMID: 22848420
  48. rs6046A allele in F7 associated with decreased blood pressure levels (P PMID: 22815813
  49. Intracellular depletion of GTP results in upregulation of coagulation factor VII. PMID: 23050902
  50. functional analysis of lethal factor VII deficiency due to novel mutations in the F7 promoter reveals disruption of HNF4 binding site PMID: 22628013


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed